

Charles A Schiffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9186742/publications.pdf>

Version: 2024-02-01

112
papers

16,559
citations

126708

33
h-index

33814

99
g-index

114
all docs

114
docs citations

114
times ranked

11474
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy. <i>JCO Oncology Practice</i> , 2022, 18, e137-e151. | 1.4 | 4 |
| 2 | Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164. | 3.0 | 9 |
| 3 | Commentary on the prescient observations made by Emil J Freireich in <i>Effectiveness of platelet transfusion in leukemia and aplastic anemia</i> (Transfusion 1966; 6: 50â€“54). <i>Transfusion</i> , 2022, 62, 267-272. | 0.8 | 2 |
| 4 | An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2022, 15, 393-402. | 1.0 | 0 |
| 5 | Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2641-2649. | 1.7 | 4 |
| 6 | Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1213-1215. | 1.3 | 1 |
| 7 | Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42. | 3.4 | 51 |
| 8 | The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. <i>Cancer</i> , 2021, 127, 93-102. | 2.0 | 5 |
| 9 | Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483. | 0.6 | 40 |
| 10 | Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2046-2049. | 1.3 | 4 |
| 11 | Asciminib for CML: same target, new arrow. <i>Blood</i> , 2021, 138, 2009-2010. | 0.6 | 3 |
| 12 | Promoting Apoptosis with Venetoclax â€” A Benefit for Older Patients with AML. <i>New England Journal of Medicine</i> , 2020, 383, 677-679. | 13.9 | 4 |
| 13 | Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 245-256. | 1.9 | 9 |
| 14 | Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML. <i>Blood</i> , 2020, 136, 44-45. | 0.6 | 7 |
| 15 | Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?. <i>Haematologica</i> , 2020, 105, 2738-2745. | 1.7 | 28 |
| 16 | An Important Gap in Informed Consent Documents for Oncology Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1399. | 3.4 | 10 |
| 17 | The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2019, 79, 1-2. | 0.4 | 7 |
| 18 | Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogenous leukemia â€” You can do this at home if you read the instructions. <i>Haematologica</i> , 2019, 104, 1508-1511. | 1.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 1253-1258. | 1.9 | 16 |
| 20 | Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. <i>Cancer</i> , 2019, 125, 135-143. | 2.0 | 20 |
| 21 | Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health. <i>Blood</i> , 2019, 134, 842-842. | 0.6 | 3 |
| 22 | Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 705-705. | 0.6 | 3 |
| 23 | Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359. | 1.1 | 15 |
| 24 | Diagnosis and Treatment of Chronic Myeloid Leukemia. , 2018, , 49-68. | | 2 |
| 25 | Epigenetic modification as therapy for acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 242-244. | 2.0 | 3 |
| 26 | Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 129-133. | 2.5 | 14 |
| 27 | Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 283-299. | 0.8 | 217 |
| 28 | To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia. <i>Haematologica</i> , 2018, 103, 1756-1757. | 1.7 | 4 |
| 29 | The evolution of dasatinib dosage over the years and its relevance to other anticancer medications. <i>Cancer</i> , 2018, 124, 2687-2689. | 2.0 | 5 |
| 30 | Supportive Care for Patients with Leukemia: A Historical Perspective. , 2018, , 1039-1045. | | 0 |
| 31 | Transplantation for Myeloma – Now or Later?. <i>New England Journal of Medicine</i> , 2017, 376, 1378-1379. | 13.9 | 5 |
| 32 | Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24. | 2.7 | 24 |
| 33 | ReCAP: Pattern of Duplicate Presentations at National Hematology-Oncology Meetings: Influence of the Pharmaceutical Industry. <i>Journal of Oncology Practice</i> , 2016, 12, 252-253. | 2.5 | 4 |
| 34 | Dasatinib in imatinib-resistant or intolerant chronic phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180034. <i>American Journal of Hematology</i> , 2016, 91, 869-874. | 2.0 | 145 |
| 35 | Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407. | 2.0 | 47 |
| 36 | Bronchoscopy can be done safely in patients with thrombocytopenia. <i>Transfusion</i> , 2016, 56, 344-348. | 0.8 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute, 2016, 108, djw003. | 3.0 | 82 |
| 38 | They took a mulligan and mostly got it right – the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation. Transfusion, 2014, 54, 2372-2374. | 0.8 | 6 |
| 39 | Optimal dose and schedule of consolidation in AAML: Is there a standard?. Best Practice and Research in Clinical Haematology, 2014, 27, 259-264. | 0.7 | 8 |
| 40 | Should all adults with acute lymphocytic leukemia receive allogeneic stem cell transplantation in first remission?. International Journal of Hematologic Oncology, 2014, 3, 325-334. | 0.7 | 0 |
| 41 | Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results. Blood, 2014, 124, 520-520. | 0.6 | 3 |
| 42 | What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. Blood, 2014, 124, 738-738. | 0.6 | 6 |
| 43 | Severe Thrombocytopenia Does Not Increase Bleeding Complications in Patients Undergoing Bronchoscopy. Blood, 2014, 124, 4293-4293. | 0.6 | 0 |
| 44 | Prophylactic platelet transfusion is frequently not necessary. Nature Reviews Clinical Oncology, 2013, 10, 431-432. | 12.5 | 11 |
| 45 | Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2013, 31, 1357-1370. | 0.8 | 278 |
| 46 | Acute myeloid leukaemia in adults. Lancet, The, 2013, 381, 484-495. | 6.3 | 470 |
| 47 | If at First You Don't Succeed: Stem-Cell Transplantation for Acute Myeloid Leukemia After First Relapse. Journal of Clinical Oncology, 2013, 31, 1259-1261. | 0.8 | 1 |
| 48 | Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 3906-3906. | 0.6 | 9 |
| 49 | First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice. Oncology, 2013, 27, 780, 825. | 0.4 | 1 |
| 50 | Which TKI should be recommended as initial treatment for CML in chronic phase?. Oncology, 2012, 26, 912, 914. | 0.4 | 1 |
| 51 | What to do if there is no evidence? The issue of surgical procedures in patients with thrombocytopenia. Transfusion, 2011, 51, 2262-2264. | 0.8 | 10 |
| 52 | Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leukemia Research, 2011, 35, e1-e3. | 0.4 | 24 |
| 53 | Very late recurrences of leukemia: Why does leukemia awake after many years of dormancy?. Leukemia Research, 2011, 35, 139-144. | 0.4 | 27 |
| 54 | CML: how low can you go?. Blood, 2010, 116, 3686-3687. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 88-94. | 1.2 | 3 |
| 56 | “œAm Older, Not Elderly,” Said the Patient With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 521-523. | 0.8 | 33 |
| 57 | Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib. <i>Blood</i> , 2010, 116, 358-358. | 0.6 | 10 |
| 58 | Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. <i>Leukemia Research</i> , 2009, 33, 561-564. | 0.4 | 12 |
| 59 | Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. <i>Biologics: Targets and Therapy</i> , 2009, 3, 205-14. | 3.0 | 8 |
| 60 | World Health Organization and International Prognostic Scoring System: The Limitations of Current Classification Systems in Assessing Prognosis and Determining Appropriate Therapy in Myelodysplastic Syndromes. <i>Seminars in Hematology</i> , 2008, 45, 3-7. | 1.8 | 18 |
| 61 | Molecular characterization of AML: A significant advance or just another prognostic factor?. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 621-628. | 0.7 | 7 |
| 62 | Current treatment options and strategies for myelodysplastic syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1667-1678. | 0.9 | 3 |
| 63 | Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. <i>Blood</i> , 2008, 111, 1774-1780. | 0.6 | 140 |
| 64 | Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. <i>Current Opinion in Hematology</i> , 2008, 15, 134-139. | 1.2 | 2 |
| 65 | BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2007, 357, 258-265. | 13.9 | 169 |
| 66 | Myelodysplasia: The good, the fair and the ugly. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 49-55. | 0.7 | 6 |
| 67 | Advances in MDS. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 450-2. | 0.3 | 0 |
| 68 | Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <i>Blood</i> , 2006, 108, 419-425. | 0.6 | 1,395 |
| 69 | “œAcute myelogenous leukemia like” translocations in CML blast crisis: Two new cases of inv(16)/t(16;16) and a review of the literature. <i>Leukemia Research</i> , 2006, 30, 225-232. | 0.4 | 13 |
| 70 | Granulocyte transfusion therapy 2006: The comeback kid?. <i>Medical Mycology</i> , 2006, 44, 383-386. | 0.3 | 33 |
| 71 | Clinical Issues in the Management of Patients with Myelodysplasia. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 205-210. | 0.9 | 16 |
| 72 | Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.. <i>Blood</i> , 2006, 108, 250-250. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. <i>Blood</i> , 2005, 105, 3420-3427. | 0.6 | 125 |
| 74 | Divide and conquer: stomping leukemia cells by stimulating them to grow. <i>Blood</i> , 2005, 106, 3-4. | 0.6 | 10 |
| 75 | Use of myeloid growth factors for patients with febrile neutropenia: Plus Ça Change, Plus C'est La Mère Chose. <i>Pediatric Blood and Cancer</i> , 2005, 45, 242-243. | 0.8 | 0 |
| 76 | "3+7" therapy for the treatment of acute myeloid leukemia. PRO. <i>Clinical Advances in Hematology and Oncology</i> , 2005, 3, 127-9. | 0.3 | 0 |
| 77 | Inhibition of Multiple Myeloma Cell Adhesion to Fibronectin by Ephrin Ligation.. <i>Blood</i> , 2004, 104, 2360-2360. | 0.6 | 0 |
| 78 | Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649. | 0.8 | 2,425 |
| 79 | Hematopoietic Growth Factors and the Future of Therapeutic Research on Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 349, 727-729. | 13.9 | 29 |
| 80 | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , 2002, 100, 4325-4336. | 0.6 | 1,444 |
| 81 | Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937. | 0.6 | 943 |
| 82 | Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539. | 0.6 | 1,096 |
| 83 | A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. <i>Blood</i> , 2002, 100, 1965-1971. | 0.6 | 534 |
| 84 | Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2002, 20, 2429-2440. | 0.8 | 1,735 |
| 85 | Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. <i>Blood</i> , 2001, 98, 548-553. | 0.6 | 197 |
| 86 | Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. <i>Journal of Clinical Oncology</i> , 2001, 19, 1519-1538. | 0.8 | 546 |
| 87 | Acute myeloid leukemia in adults: where do we go from here?. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, S45-S52. | 1.1 | 22 |
| 88 | 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. <i>Journal of Clinical Oncology</i> , 2000, 18, 3558-3585. | 0.8 | 761 |
| 89 | Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. <i>Journal of Clinical Oncology</i> , 1999, 17, 3767-3775. | 0.8 | 290 |
| 90 | Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. <i>Journal of Clinical Oncology</i> , 1999, 17, 3110-3116. | 0.8 | 393 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Opportunities for the use of thrombopoietic growth factors. <i>Stem Cells</i> , 1998, 16, 249-253. | 1.4 | 0 |
| 92 | Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia group B during the period 1971-1988. , 1997, 80, 1936-1944. | | 113 |
| 93 | Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22). <i>Blood</i> , 1997, 90, 1643-1648. | 0.6 | 5 |
| 94 | White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. The Trap Study Group. <i>Transfusion</i> , 1995, 35, 13-19. | 0.8 | 86 |
| 95 | Chemotherapy-induced lactose intolerance in adults. <i>Cancer</i> , 1994, 74, 1629-1633. | 2.0 | 27 |
| 96 | Use of â€ˆSplitâ€™™ Plateletpheresis Products for Alloimmunized Patients. <i>Vox Sanguinis</i> , 1994, 67, 272-274. | 0.7 | 10 |
| 97 | Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1994, 331, 896-903. | 13.9 | 1,328 |
| 98 | Should All Platelet Concentrates Issued Be Leukocyteâ€™Poor?. <i>Vox Sanguinis</i> , 1992, 62, 57-64. | 0.7 | 26 |
| 99 | Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. <i>American Journal of Hematology</i> , 1990, 33, 238-243. | 2.0 | 12 |
| 100 | Granulocyte transfusion therapy and amphotericin B: Adverse reactions?. <i>American Journal of Hematology</i> , 1989, 31, 102-108. | 2.0 | 50 |
| 101 | Philadelphia chromosome-positive acute leukemia: Morphologic and clinical correlations. <i>American Journal of Hematology</i> , 1987, 25, 311-324. | 2.0 | 18 |
| 102 | Clinical and cytogenetic features of familial erythroleukaemia. <i>British Journal of Haematology</i> , 1987, 65, 313-320. | 1.2 | 15 |
| 103 | Differentiation of Leukemia Cells to Polymorphonuclear Leukocytes in Patients with Acute Nonlymphocytic Leukemia. <i>New England Journal of Medicine</i> , 1986, 315, 15-24. | 13.9 | 296 |
| 104 | Promyelocytic blast crisis in chronic granulocytic leukemia with 15;17 translocation. <i>Leukemia Research</i> , 1984, 8, 1019-1023. | 0.4 | 44 |
| 105 | Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. <i>Cancer</i> , 1984, 53, 557-562. | 2.0 | 46 |
| 106 | Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. <i>American Journal of Hematology</i> , 1983, 14, 363-369. | 2.0 | 93 |
| 107 | Acute promyelocytic leukemiaâ€™clinical management of 15 patients. <i>American Journal of Hematology</i> , 1980, 8, 347-359. | 2.0 | 63 |
| 108 | Improved prognosis for granulocytopenic patients with gram-negative bacteremia. <i>American Journal of Medicine</i> , 1980, 68, 643-648. | 0.6 | 196 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | The Significance of Abnormal Circulating Cells in Patients with Hodgkin's Disease. British Journal of Haematology, 1975, 31, 177-183. | 1.2 | 8 |
| 110 | Haematologic Cancers. , 0, , 141-148. | | 0 |
| 111 | Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biologics: Targets and Therapy, 0, , 205. | 3.0 | 2 |
| 112 | Haematologic Cancers: Challenges in Developing New Therapeutic Approaches. , 0, , 167-175. | | 0 |